New drug fabhalta tracked in kidney disease patients
NCT ID NCT07156149
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 50 people with C3 glomerulopathy, a rare kidney disease, who are taking the drug Fabhalta. Researchers want to see how safe the drug is and how well it works in everyday clinical settings. They will track infections, side effects, and kidney function over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fabhalta (iptacopan)
What this could lead to
If successful, this could confirm that Fabhalta is a safe and effective treatment option for managing C3 glomerulopathy in everyday medical practice.
What could go wrong
This is an observational study with no control group, so results may not prove cause and effect. The small size (50 patients) limits how broadly findings can be applied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Nagoya, Aichi-ken, 466-8650, Japan
-
Novartis Investigative Site
Toyoake, Aichi-ken, 4701192, Japan
-
Novartis Investigative Site
Hirosaki, Aomori, 0368563, Japan
-
Novartis Investigative Site
Chiba, Chiba, 2608677, Japan
-
Novartis Investigative Site
Fukuoka, Fukuoka, 810-8563, Japan
-
Novartis Investigative Site
Kitakyushu, Fukuoka, 8028555, Japan
-
Novartis Investigative Site
Sapporo, Hokkaido, 0040041, Japan
-
Novartis Investigative Site
Sapporo, Hokkaido, 0608604, Japan
-
Novartis Investigative Site
Tsukuba, Ibaraki, 3058576, Japan
-
Novartis Investigative Site
Komatsu, Ishikawa-ken, 923-0961, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, 231-8682, Japan
-
Novartis Investigative Site
Tosa-gun, Kyoto, 629-2261, Japan
-
Novartis Investigative Site
Tsu, Mie-ken, 514-8507, Japan
-
Novartis Investigative Site
Nagasaki, Nagasaki, 852-8501, Japan
-
Novartis Investigative Site
Suita, Osaka, 565-0871, Japan
-
Novartis Investigative Site
Takatsuki, Osaka, 5698686, Japan
-
Novartis Investigative Site
Kusatsu, Shiga, 525-8585, Japan
-
Novartis Investigative Site
Ohtsu, Shiga, 5202192, Japan
-
Novartis Investigative Site
Shizuoka, Shizuoka, 420-8527, Japan
-
Novartis Investigative Site
Shimotsuga Gun, Tochigi, 3210293, Japan
-
Novartis Investigative Site
Tokushima, Tokushima, 7708503, Japan
-
Novartis Investigative Site
Bunkyo-ku, Tokyo, 1138519, Japan
-
Novartis Investigative Site
Fuchū, Tokyo, 1838561, Japan
-
Novartis Investigative Site
Nakano City, Tokyo, 164-8607, Japan
-
Novartis Investigative Site
Shinjuku Ku, Tokyo, 1628666, Japan
-
Novartis Investigative Site
Hiroshima, 7348530, Japan
-
Novartis Investigative Site
Ishikawa, 9208641, Japan
-
Novartis Investigative Site
Nara, 630-8581, Japan
-
Novartis Investigative Site
Wakayama, 640-8558, Japan